| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Resynchronization Therapy | 42 | 2024 | 77 | 12.520 |
Why?
|
| Bundle-Branch Block | 26 | 2024 | 59 | 7.600 |
Why?
|
| Bundle of His | 23 | 2024 | 49 | 7.470 |
Why?
|
| Electrocardiography | 34 | 2024 | 507 | 5.560 |
Why?
|
| Defibrillators, Implantable | 22 | 2024 | 147 | 5.360 |
Why?
|
| Heart Failure | 31 | 2024 | 1341 | 4.860 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 378 | 4.490 |
Why?
|
| Tachycardia, Ventricular | 18 | 2024 | 125 | 3.490 |
Why?
|
| Catheter Ablation | 24 | 2024 | 257 | 3.250 |
Why?
|
| Cardiac Pacing, Artificial | 17 | 2024 | 105 | 3.050 |
Why?
|
| Heart Conduction System | 17 | 2024 | 123 | 2.950 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 12 | 2024 | 59 | 2.060 |
Why?
|
| Arrhythmias, Cardiac | 14 | 2024 | 202 | 1.720 |
Why?
|
| Heart Rate | 11 | 2024 | 501 | 1.590 |
Why?
|
| Heart Ventricles | 14 | 2020 | 795 | 1.430 |
Why?
|
| Treatment Outcome | 49 | 2024 | 8724 | 1.420 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 7 | 2019 | 19 | 1.170 |
Why?
|
| Pacemaker, Artificial | 7 | 2024 | 97 | 1.110 |
Why?
|
| Humans | 112 | 2024 | 92335 | 1.100 |
Why?
|
| Stroke Volume | 5 | 2024 | 500 | 1.090 |
Why?
|
| Electric Countershock | 4 | 2024 | 58 | 1.030 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 4 | 2024 | 27 | 1.030 |
Why?
|
| Aged | 57 | 2024 | 19946 | 0.990 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2019 | 66 | 0.890 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2024 | 56 | 0.890 |
Why?
|
| Heart Septum | 3 | 2024 | 47 | 0.830 |
Why?
|
| Ventricular Function, Left | 9 | 2024 | 639 | 0.820 |
Why?
|
| Cardiomyopathies | 7 | 2020 | 272 | 0.800 |
Why?
|
| Middle Aged | 46 | 2024 | 27048 | 0.800 |
Why?
|
| Body Surface Potential Mapping | 5 | 2021 | 25 | 0.790 |
Why?
|
| Female | 65 | 2024 | 47910 | 0.790 |
Why?
|
| Male | 64 | 2024 | 43922 | 0.780 |
Why?
|
| Echocardiography | 9 | 2019 | 971 | 0.780 |
Why?
|
| Prospective Studies | 23 | 2024 | 4464 | 0.750 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 205 | 0.750 |
Why?
|
| Atrioventricular Block | 4 | 2024 | 27 | 0.720 |
Why?
|
| Heart Atria | 4 | 2024 | 289 | 0.710 |
Why?
|
| Anticoagulants | 2 | 2023 | 448 | 0.650 |
Why?
|
| Purkinje Fibers | 1 | 2019 | 27 | 0.610 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 25 | 0.610 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 72 | 0.590 |
Why?
|
| Bradycardia | 3 | 2024 | 43 | 0.570 |
Why?
|
| Action Potentials | 3 | 2024 | 604 | 0.540 |
Why?
|
| Retrospective Studies | 26 | 2024 | 9682 | 0.540 |
Why?
|
| Atrioventricular Node | 5 | 2024 | 36 | 0.530 |
Why?
|
| Cicatrix | 4 | 2024 | 70 | 0.520 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 151 | 0.510 |
Why?
|
| Registries | 4 | 2024 | 904 | 0.500 |
Why?
|
| Atrial Flutter | 4 | 2020 | 37 | 0.490 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 19 | 0.480 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 211 | 0.470 |
Why?
|
| Hospitalization | 4 | 2018 | 926 | 0.450 |
Why?
|
| Cause of Death | 1 | 2015 | 270 | 0.440 |
Why?
|
| Ventricular Fibrillation | 4 | 2024 | 69 | 0.400 |
Why?
|
| Incidence | 7 | 2024 | 1658 | 0.390 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 55 | 0.380 |
Why?
|
| Follow-Up Studies | 15 | 2024 | 3775 | 0.380 |
Why?
|
| Equipment Failure | 1 | 2012 | 122 | 0.370 |
Why?
|
| Myocarditis | 1 | 2012 | 56 | 0.370 |
Why?
|
| Risk Factors | 14 | 2024 | 5703 | 0.360 |
Why?
|
| Growth Differentiation Factor 10 | 1 | 2011 | 1 | 0.360 |
Why?
|
| Postoperative Complications | 3 | 2021 | 2452 | 0.350 |
Why?
|
| Antigens, Ly | 1 | 2011 | 37 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2014 | 335 | 0.340 |
Why?
|
| Epicardial Mapping | 2 | 2021 | 10 | 0.340 |
Why?
|
| Sick Sinus Syndrome | 2 | 2021 | 9 | 0.330 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 128 | 0.320 |
Why?
|
| Ventricular Remodeling | 7 | 2020 | 109 | 0.320 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 268 | 0.320 |
Why?
|
| Device Removal | 2 | 2021 | 165 | 0.310 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 332 | 0.300 |
Why?
|
| Mitral Valve | 3 | 2020 | 275 | 0.290 |
Why?
|
| GTPase-Activating Proteins | 1 | 2008 | 67 | 0.280 |
Why?
|
| Wnt Proteins | 1 | 2008 | 130 | 0.280 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 130 | 0.280 |
Why?
|
| Time Factors | 8 | 2024 | 5428 | 0.270 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 1761 | 0.270 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6916 | 0.270 |
Why?
|
| Recurrence | 8 | 2024 | 1180 | 0.260 |
Why?
|
| beta Catenin | 1 | 2008 | 264 | 0.250 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2007 | 134 | 0.250 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 166 | 0.250 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 164 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2019 | 2979 | 0.240 |
Why?
|
| Ventricular Septum | 2 | 2024 | 15 | 0.240 |
Why?
|
| Risk Assessment | 7 | 2024 | 2370 | 0.230 |
Why?
|
| Myocardium | 2 | 2020 | 586 | 0.220 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1244 | 0.220 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2004 | 9 | 0.220 |
Why?
|
| Syncope, Vasovagal | 1 | 2024 | 5 | 0.220 |
Why?
|
| Patient Selection | 2 | 2022 | 689 | 0.210 |
Why?
|
| Hemodynamics | 2 | 2024 | 758 | 0.210 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 11 | 0.210 |
Why?
|
| Mental Health | 1 | 2024 | 183 | 0.200 |
Why?
|
| Electrodes, Implanted | 3 | 2012 | 200 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 152 | 0.200 |
Why?
|
| Medicare | 3 | 2024 | 436 | 0.190 |
Why?
|
| United States | 8 | 2024 | 7366 | 0.190 |
Why?
|
| Vaccination | 1 | 2024 | 286 | 0.190 |
Why?
|
| Feasibility Studies | 6 | 2021 | 800 | 0.190 |
Why?
|
| Heart-Assist Devices | 4 | 2018 | 864 | 0.190 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 446 | 0.180 |
Why?
|
| Ventricular Premature Complexes | 1 | 2021 | 8 | 0.180 |
Why?
|
| Prognosis | 5 | 2023 | 3875 | 0.180 |
Why?
|
| Treatment Failure | 3 | 2017 | 289 | 0.180 |
Why?
|
| Crohn Disease | 2 | 2007 | 772 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 304 | 0.180 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 56 | 0.170 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 10 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2021 | 402 | 0.170 |
Why?
|
| Pulmonary Veins | 2 | 2012 | 93 | 0.170 |
Why?
|
| Gadolinium | 1 | 2020 | 104 | 0.170 |
Why?
|
| Global Health | 2 | 2021 | 199 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1921 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 128 | 0.160 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 60 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 121 | 0.160 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 14 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 152 | 0.150 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 324 | 0.150 |
Why?
|
| Tachycardia | 1 | 2018 | 36 | 0.140 |
Why?
|
| Computer Security | 1 | 2018 | 18 | 0.140 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2018 | 2 | 0.140 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 252 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 358 | 0.140 |
Why?
|
| Quality of Life | 2 | 2024 | 1743 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 431 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2018 | 126 | 0.130 |
Why?
|
| Forecasting | 2 | 2015 | 311 | 0.130 |
Why?
|
| Cardiology | 1 | 2017 | 125 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 808 | 0.120 |
Why?
|
| Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.120 |
Why?
|
| Coronary Angiography | 2 | 2014 | 248 | 0.110 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1179 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 33 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 601 | 0.110 |
Why?
|
| Cardiac Conduction System Disease | 2 | 2023 | 7 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 474 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 119 | 0.100 |
Why?
|
| Walking | 1 | 2014 | 96 | 0.100 |
Why?
|
| Animals | 4 | 2022 | 28055 | 0.100 |
Why?
|
| Pharyngitis | 1 | 2012 | 15 | 0.100 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 35 | 0.100 |
Why?
|
| Creatine Kinase | 1 | 2012 | 53 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 27555 | 0.100 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 6 | 0.100 |
Why?
|
| Troponin T | 1 | 2012 | 41 | 0.100 |
Why?
|
| Chest Pain | 1 | 2012 | 47 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 190 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 236 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 190 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 330 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2024 | 304 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1275 | 0.090 |
Why?
|
| Equipment Design | 1 | 2012 | 420 | 0.090 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 2 | 0.090 |
Why?
|
| Smad3 Protein | 1 | 2011 | 26 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 46 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 88 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2013 | 340 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 307 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 374 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 2734 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 102 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2012 | 297 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 415 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 402 | 0.080 |
Why?
|
| Biomarkers | 2 | 2012 | 1847 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2011 | 3509 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 6619 | 0.070 |
Why?
|
| Axin Protein | 1 | 2008 | 4 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 44 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2008 | 49 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1593 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cytosol | 1 | 2008 | 195 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1905 | 0.070 |
Why?
|
| Contrast Media | 2 | 2024 | 1077 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 2324 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1592 | 0.070 |
Why?
|
| Behavior | 1 | 2007 | 83 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2793 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 120 | 0.060 |
Why?
|
| Perception | 1 | 2007 | 183 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 863 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2102 | 0.060 |
Why?
|
| Clinical Clerkship | 1 | 2007 | 120 | 0.060 |
Why?
|
| Mice | 2 | 2011 | 12137 | 0.060 |
Why?
|
| Zebrafish | 1 | 2008 | 326 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1308 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2037 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 986 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2007 | 308 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 438 | 0.060 |
Why?
|
| Ventricular Pressure | 1 | 2024 | 44 | 0.060 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2024 | 11 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1297 | 0.050 |
Why?
|
| Heart Injuries | 1 | 2024 | 22 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2009 | 0.050 |
Why?
|
| Syncope | 1 | 2024 | 36 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1784 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2024 | 129 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3374 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 2503 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1206 | 0.050 |
Why?
|
| Atropine | 1 | 2023 | 60 | 0.050 |
Why?
|
| Heart Block | 1 | 2023 | 31 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2024 | 172 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 219 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 390 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1891 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 375 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 178 | 0.050 |
Why?
|
| Students, Medical | 1 | 2007 | 434 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 218 | 0.050 |
Why?
|
| Mortality | 1 | 2021 | 150 | 0.040 |
Why?
|
| Survival Rate | 2 | 2015 | 1926 | 0.040 |
Why?
|
| Endocardium | 1 | 2020 | 98 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 955 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 359 | 0.040 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 33 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 1514 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1500 | 0.040 |
Why?
|
| Pericardium | 1 | 2019 | 71 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1733 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 119 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 56 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 583 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 202 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 607 | 0.030 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 7 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 36 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 57 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Capillaries | 1 | 2014 | 87 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 47 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 33 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 97 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2012 | 159 | 0.020 |
Why?
|
| Child | 1 | 2023 | 7307 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1118 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 305 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 871 | 0.020 |
Why?
|
| Adolescent | 1 | 2004 | 9492 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 22 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 193 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 661 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 900 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 966 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 995 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 886 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2014 | 774 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 38 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 109 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1150 | 0.020 |
Why?
|
| Japan | 1 | 2007 | 305 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 899 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 652 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 658 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 630 | 0.010 |
Why?
|